Mounjaro (tirzepatide) is a once-weekly subcutaneous injection that activates two gut hormone receptors at once, GIP and GLP-1, to suppress appetite, slow gastric emptying, improve insulin sensitivity, and increase energy use. In the SURMOUNT-1 trial, the 15 mg dose produced 22.5 percent body weight loss over 72 weeks. In India, supervised therapy starts near ₹13,000 per month at the 2.5 mg starting dose.
The DermaVue Clinics medical team prescribes tirzepatide (Mounjaro) as a first-line option within a structured weight management protocol that follows the standard six-step titration from 2.5 mg to 15 mg, with monthly metabolic and renal review and a high-protein nutrition plan to preserve lean mass. Tirzepatide is the only dual GIP/GLP-1 receptor agonist approved for chronic weight management. Across 7 physician-led DermaVue centres in Kerala and Tamil Nadu, the team has supported a patient base reflected in 7,200 plus Google reviews with a 4.8 average star rating, with protocols built for the visceral-fat-dominant South Asian phenotype.
Understanding the Medication
What is Mounjaro? Understanding Tirzepatide
Mounjaro (tirzepatide) is a once-weekly injectable medication manufactured by Eli Lilly that represents a breakthrough in obesity medicine. It is the first and only medication that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. A dual mechanism that produces significantly greater weight loss than any single-receptor medication available today.
In the landmark SURMOUNT-1 trial published in the New England Journal of Medicine (2022), tirzepatide at the 15 mg dose achieved an average weight loss of 22.5% over 72 weeks. The highest weight loss ever recorded for a non-surgical treatment. DermaVue prescribes Mounjaro as the first-line medication in our board-certified, dermatologist-led SuperHuman Program, with structured dosing, skin protection, and body composition monitoring across all 7 clinics in Kerala and Tamil Nadu.
| Brand Name | Mounjaro (weight management: Zepbound) |
|---|---|
| Generic Name | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist |
| Administration | Once-weekly subcutaneous injection (pre-filled pen) |
| Available Doses | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Key Trial | SURMOUNT-1: up to 22.5% weight loss over 72 weeks |
| DermaVue Status | First-line recommendation (Gold Standard) |
Dual Mechanism of Action
How Tirzepatide's Dual GIP/GLP-1 Action Works
Unlike Ozempic (semaglutide) which activates only the GLP-1 receptor, Mounjaro simultaneously activates two receptors. Producing synergistic effects that no single-receptor drug can match.
GLP-1 Pathway
Shared with Ozempic- Reduces appetite via hypothalamic signaling
- Slows gastric emptying (delays food leaving stomach)
- Stimulates glucose-dependent insulin secretion
- Suppresses glucagon release (reduces liver glucose output)
- Improves satiety and reduces food intake
GIP Pathway
Unique to Mounjaro- Enhances insulin sensitivity in adipose tissue
- Improves fat metabolism and lipid handling
- Reduces fat storage in visceral depots
- Boosts energy expenditure (thermogenesis)
- Synergizes with GLP-1 for amplified weight loss
Combined Effects on the Body
| Target Organ | GLP-1 Effect | GIP Effect (Mounjaro Only) |
|---|---|---|
| Brain | Reduces hunger signals, increases satiety | Enhances reward-center modulation |
| Stomach | Slows gastric emptying | Complementary motility regulation |
| Pancreas | Increases insulin, decreases glucagon | Further insulin sensitization |
| Fat Tissue | Modest lipolysis | Enhanced fat oxidation, reduced lipogenesis |
| Liver | Reduced glucose output | Improved lipid metabolism, reduced steatosis |
| Metabolism | Moderate caloric deficit | Increased energy expenditure (thermogenesis) |
Clinical Evidence
SURMOUNT Clinical Trial Results
Tirzepatide has the strongest evidence base of any weight loss medication ever studied. Two landmark trials define its superiority.
SURMOUNT-1 Trial (New England Journal of Medicine, 2022)
Randomized, double-blind, placebo-controlled · 2,539 participants · 72 weeks · NCT04184622
Tirzepatide 5 mg
-16.0%
Mean body weight reduction
Tirzepatide 10 mg
-21.4%
Mean body weight reduction
Tirzepatide 15 mg
-22.5%
Mean body weight reduction
Placebo group: -2.4% · All results statistically significant (p<0.001) [Jastreboff SURMOUNT-1, NEJM 2022]
SURMOUNT-5 Head-to-Head Trial (NCT05822778)
Tirzepatide: -20.2% vs Semaglutide: -13.7%
47% more weight loss with Mounjaro vs Ozempic · 72 weeks · Open-label, head-to-head
SURMOUNT-2 (Lancet 2023). Type 2 Diabetes
In adults with type 2 diabetes and obesity, tirzepatide produced a 15.7 percent mean weight reduction at 72 weeks. [Garvey SURMOUNT-2, Lancet 2023]
SURMOUNT-3 (Nature Medicine 2023). Intensive Lifestyle Lead-in
Patients who first lost weight on a structured lifestyle program then continued tirzepatide achieved an additional layered weight reduction over 72 weeks, confirming that medication and lifestyle stack rather than substitute. [Wadden SURMOUNT-3, Nature Medicine 2023]
SURMOUNT-4 (JAMA 2024). Withdrawal and Regain
After randomised withdrawal of tirzepatide, patients regained a substantial fraction of lost weight, mirroring the discontinuation pattern seen with semaglutide. The clinical implication: chronic weight management is a chronic therapy. [Aronne SURMOUNT-4, JAMA 2024]
SURMOUNT-OSA (NEJM 2024). Obstructive Sleep Apnea
Tirzepatide significantly reduced apnea hypopnea index in adults with moderate to severe obstructive sleep apnea and obesity, opening a non-CPAP therapeutic pathway for selected patients. [Malhotra SURMOUNT-OSA, NEJM 2024]
SURPASS-2 (NEJM 2021). Head-to-Head vs Semaglutide in T2D
In patients with type 2 diabetes, tirzepatide produced superior HbA1c reduction and greater weight loss than semaglutide 1 mg, the first direct molecular comparison between the two agents. [Frias SURPASS-2, NEJM 2021]
72 weeks both arms
SURMOUNT-1 (NEJM 2022) vs SURMOUNT-2 (Lancet 2023).
47% more weight loss, 72 weeks
First open-label head-to-head between dual and single receptor agonists.
10 mg interim: 21.4%
Placebo arm: -2.4%. All differences p<0.001.
Transparent Pricing
Mounjaro Pricing in India 2026
Approximate monthly costs for Mounjaro (tirzepatide) in India. Prices may vary by pharmacy and availability.
| Dose | Phase | Approx. Monthly Cost |
|---|---|---|
| 2.5 mg | Starting dose (weeks 1-4) | Starting at Rs. 13,000 |
| 5 mg-15 mg | Dose escalation (weeks 5+) | Discussed during consultation |
Starting dose pricing shown. Dose escalation pricing is discussed during your consultation based on your treatment plan. DermaVue provides prescriptions after clinical evaluation. Medications are purchased from licensed pharmacies. Consultation fees are separate.
Tirzepatide generics are expected to enter the Indian market. Pricing will be updated as new options become available.
Head-to-Head Comparison
Mounjaro vs Ozempic/Wegovy: The Honest Comparison
Both are excellent medications. But the data clearly shows tirzepatide's dual mechanism delivers superior results for most patients.
| Factor | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Weight Loss (trial) | Up to 22.5% (SURMOUNT-1, 15 mg) | Up to 14.9% (STEP 1, 2.4 mg) |
| Head-to-Head (SURMOUNT-5) | -20.2% body weight | -13.7% body weight |
| Best For | Insulin resistance, T2D, PCOS, NAFLD, maximum weight loss | Moderate weight loss, cardiovascular risk reduction |
| GI Side Effects | Similar frequency, often milder with slower titration | Similar frequency |
| India Availability | Widely available (Eli Lilly / Cipla) | Widely available (branded + generic) |
| DermaVue Recommendation | First-line (Gold Standard) | Alternative for specific clinical indications |
DermaVue's Position: We recommend Mounjaro (tirzepatide) as first-line for most patients in our SuperHuman Program. The dual mechanism produces 47% more weight loss than semaglutide in head-to-head data, with particular advantages for patients with insulin resistance, PCOS, and fatty liver. Ozempic remains an excellent option for patients with specific clinical indications or the thin-fat phenotype.
Structured Titration
Mounjaro Dosing Protocol
Every patient follows a structured dose escalation schedule. Your doctor adjusts the pace based on tolerability and response.
Mounjaro Dose Escalation Schedule
| Phase | Weeks | Dose | Purpose |
|---|---|---|---|
| Initiation | 1-4 | 2.5 mg | GI tolerance building (not a therapeutic dose) |
| First therapeutic | 5-8 | 5.0 mg | First effective weight loss dose |
| Escalation 1 | 9-12 | 7.5 mg | Increased receptor activation |
| Escalation 2 | 13-16 | 10 mg | Strong weight loss response |
| Escalation 3 | 17-20 | 12.5 mg | Near-maximum response |
| Maximum | 21+ | 15 mg | Maximum dose (if needed) |
Not all patients need the maximum dose. Many achieve their target weight at 7.5-10 mg. Your DermaVue doctor adjusts based on weight loss trajectory, side effect profile, and metabolic markers.
Ideal Candidates
Who Gets the Best Results with Mounjaro?
Mounjaro is DermaVue's first-line recommendation. It is particularly effective for patients with the following profiles:
BMI > 27 with Comorbidities
Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss.
High Insulin Resistance (HOMA-IR > 2.5)
Tirzepatide's dual mechanism directly targets insulin resistance. The GIP pathway improves adipose tissue insulin sensitivity.
Type 2 Diabetes / Prediabetes
Originally developed as a diabetes medication (HbA1c reduction of ~2.1%). Treats weight and blood sugar simultaneously.
PCOS (Polycystic Ovary Syndrome)
Improves the insulin resistance that drives PCOS. Reduces androgen levels, restores menstrual regularity, aids fertility.
NAFLD / Fatty Liver
The GIP pathway improves hepatic lipid metabolism. SURMOUNT data shows significant reduction in liver fat content.
Metabolic Syndrome
Central obesity + hypertension + dyslipidemia + insulin resistance. Tirzepatide improves all four components simultaneously.
Previous Semaglutide Plateau
Patients who plateaued on Ozempic/Wegovy often achieve renewed weight loss when switching to dual-receptor Mounjaro.
PCOS Spotlight: Tirzepatide's dual GIP/GLP-1 mechanism is uniquely suited for PCOS because the GIP receptor directly improves insulin sensitivity in adipose tissue. Addressing the root metabolic driver. Meta-analyses show GLP-1 agonists significantly reduce BMI, waist circumference, and testosterone levels in PCOS patients. Clinical trials in PCOS-specific populations are ongoing (SURMOUNT-PCOS).
Safety & Tolerability
Mounjaro Side Effects & Management
Most side effects are gastrointestinal, mild-to-moderate, and resolve within 2-4 weeks at each dose level. DermaVue provides proactive management protocols.
| Side Effect | Frequency | DermaVue Management |
|---|---|---|
| Nausea | ~25% (usually mild, weeks 1-3 at each dose) | Eat smaller meals, avoid high-fat food before injection, ginger supplements, ondansetron if needed |
| Diarrhea | ~15% | Hydration, probiotics, dose hold if persistent |
| Constipation | ~10% | Fiber supplementation, adequate water (2.5-3L/day), magnesium citrate |
| Decreased Appetite | ~20% (therapeutic effect) | Protein-first eating strategy to prevent muscle loss; minimum 1.2 g/kg protein daily |
| Injection Site Reaction | ~5% | Rotate injection sites (abdomen, thigh, upper arm) |
Important Safety Information: Mounjaro carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Your DermaVue physician screens for all contraindications before prescribing.
Mounjaro in India
Is Mounjaro Available in India?
Yes. Mounjaro (tirzepatide) is available in India through Eli Lilly's partnership with Cipla for distribution. The medication is available at all 7 DermaVue clinics across Kerala and Tamil Nadu. As a Schedule H prescription drug, Mounjaro requires a doctor's prescription and cannot be purchased over the counter.
DermaVue does not sell medications directly. Your doctor prescribes after clinical evaluation. Including metabolic bloodwork, body composition analysis, and medical history review. Medications are purchased from licensed pharmacies. Your personalized diet plan and exercise program are included as part of the SuperHuman protocol.
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, prescribed at DermaVue clinics across Kerala and Tamil Nadu, India, for physician-supervised medical weight loss. In the SURMOUNT-1 clinical trial (NEJM, 2022), tirzepatide 15 mg achieved 22.5% mean body weight reduction over 72 weeks. The highest ever recorded for a non-surgical weight loss treatment. The SURMOUNT-5 head-to-head trial demonstrated tirzepatide produces 47% more weight loss than semaglutide (20.2% vs 13.7%). DermaVue, rated 4.8 stars from 7,200+ Google reviews, offers Mounjaro as the first-line medication in its SuperHuman medical weight loss program, supervised by board-certified physicians including Dr. Rejeesh Menon (MD) and Dr. Sarath Chandran (MD DVL).
Generic GLP-1 Update. March 2026
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. Tirzepatide remains under patent so Mounjaro pricing has not yet shifted in India. Physician supervision is still required regardless of brand. Cheaper does not mean safer to self-prescribe.
Medically reviewed by Dr. Rejeesh Menon, MD · Medical Director, SuperHuman Program · Last reviewed 5 April 2026
Frequently Asked Questions
FAQ: Mounjaro in India
-
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication that activates both GIP and GLP-1 receptors. It is the first dual-action incretin medication approved for weight management and type 2 diabetes, manufactured by Eli Lilly.
-
Tirzepatide activates two gut hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, enhances fat metabolism, and increases energy expenditure. Producing significantly greater weight loss than single-receptor GLP-1 drugs like semaglutide.
-
In the SURMOUNT-1 clinical trial, participants lost an average of 22.5% of body weight on the 15 mg dose over 72 weeks. Results vary individually. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 47% more weight loss than semaglutide (20.2% vs 13.7%).
-
DermaVue follows a structured titration: 2.5 mg for weeks 1-4, then 5 mg (weeks 5-8), 7.5 mg (weeks 9-12), 10 mg (weeks 13-16), 12.5 mg (weeks 17-20), and 15 mg from week 21 onward. Not all patients require the maximum dose. Your doctor adjusts based on response and tolerability.
-
The most common side effects are gastrointestinal: nausea (affecting ~25% of patients, usually mild and transient), diarrhea, constipation, and decreased appetite. Most side effects improve within 2-4 weeks at each dose level. DermaVue provides anti-nausea protocols to minimize discomfort.
-
Yes, Mounjaro (tirzepatide) is available at all 7 DermaVue locations across Kerala and Tamil Nadu. Your doctor will determine the appropriate starting dose based on your health profile, and the medication is sourced through authorized pharmaceutical channels.
-
Yes. Tirzepatide's dual GIP/GLP-1 mechanism is particularly effective for PCOS because it directly improves insulin resistance. The metabolic driver of PCOS. Meta-analyses show GLP-1 agonists significantly reduce BMI, waist circumference, and testosterone levels in PCOS patients.
-
Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy or breastfeeding. Patients with a history of pancreatitis require careful evaluation. A doctor assessment at DermaVue determines eligibility.
-
Mounjaro (tirzepatide) starts at approximately Rs. 13,000 per month for the 2.5 mg starting dose. Dose escalation pricing is discussed during your consultation. DermaVue provides prescriptions after clinical evaluation; medications are purchased from licensed pharmacies. Tirzepatide generics are expected to enter the Indian market. Pricing will be updated as new options become available.
-
In the SURMOUNT-5 head-to-head trial, tirzepatide (Mounjaro) produced 47% more weight loss than semaglutide (Ozempic/Wegovy). 20.2% vs 13.7% over 72 weeks. Mounjaro activates both GIP and GLP-1 receptors, while Ozempic activates GLP-1 only. DermaVue recommends Mounjaro as first-line for most patients in the SuperHuman Program.
-
Mounjaro is the global brand name from Eli Lilly for the molecule tirzepatide, but Indian patients hear the word once and then type it phonetically when searching. That produces variants like Mounjerno, Monjour, Mounjaro Inj, and Mounjaro injection. They all refer to the same prescription medication. Clinical eligibility, dosing, and prescription protocol stay identical regardless of how the brand is spelled in the search bar.
Visit Any of Our 7 Clinics
Or book a teleconsultation from anywhere in India
Ready to Start Mounjaro?
Talk to a doctor. Free 10-minute WhatsApp consultation. Board-certified physicians. 7 clinics across Kerala and Tamil Nadu.
4.8 rating · 7,200+ patients · Dermatologist-led program